Novel Approaches of Cellular Therapy in Multiple Myeloma - Focus on CART [0.03%]
新型的治疗多发性骨髓瘤的细胞疗法及其焦点CAR-T疗法
Ravi Kishore Narra,Supriya Peshin,Binod Dhakal
Ravi Kishore Narra
Background: Recent advancements in cellular therapies, particularly CAR-T and T cell engaging bispecific antibodies have significantly altered the therapeutic landscape for Multiple Myeloma. There are two U.S. FDA approve...
Clinical Challenges in Treating Cancer Associated Thrombosis: A Clinically Oriented Review [0.03%]
肿瘤相关血栓治疗的临床挑战：面向临床医生的综述
Idan Goldberg,Galia Spectre,Pia Raanani et al.
Idan Goldberg et al.
Background: Managing cancer associated thrombosis (CAT) is a significant clinical challenge due to several factors such as increased bleeding tendency, frailty, and drug - drug interactions. For many years, the drug of ch...
"Real-life" Data of Zanubrutinib in Patients with Waldenström Macroglobulinemia - A Multi-Center Retrospective Study [0.03%]
泽普生治疗华氏巨球蛋白血症患者的“真实世界”数据——一项多中心回顾性研究
Gilad Itchaki,Ohad Benjamini,Mor Levi et al.
Gilad Itchaki et al.
Introduction: Waldenström macroglobulinemia (WM) is a rare indolent lymphoma. Zanubrutinib (ZAN), a second-generation BTK inhibitor, has been approved for the treatment of WM in any line of therapy in 2021. Between Novem...
Haploidentical Allogeneic Hematopoietic Cell Transplantation following Two Courses of Venetoclax and Azacytidine Therapy in Patients over 55 Years Old with Acute Myelogenous Leukemia: Comment [0.03%]
关于维奈克拉和阿扎胞苷两个疗程治疗后接受单倍体相合造血干细胞移植治疗大于55岁急性髓系白血病患者的评论
Hinpetch Daungsupawong,Viroj Wiwanitkit
Hinpetch Daungsupawong
Historical Perspective of Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma [0.03%]
异基因造血干细胞移植治疗多发性骨髓瘤的里程碑事件及未来展望
Muhammad Faisal Aslam,Asfand Yar Cheema,Daniyal Shahid et al.
Muhammad Faisal Aslam et al.
Background: Advances in novel therapies have improved outcomes for multiple myeloma (MM) patients and the use of allo-SCT has decreased. Current guidelines no longer support allo-SCT as consolidation therapy for newly dia...
Coronary Artery Disease and Microvascular Ischemia in Patients with Cardiac Amyloidosis [0.03%]
心脏淀粉样变患者冠状动脉疾病和微血管缺血的风险增加
Osnat Itzhaki Ben Zadok,Iuliana Vaxman,Sara Hoss et al.
Osnat Itzhaki Ben Zadok et al.
Introduction: The prevalence of preexisting obstructive coronary artery disease (CAD) and the occurrence of anginal chest pain as a presenting symptom in patients with light-chain (AL) and transthyretin (ATTR) cardiac amy...
RESULTS OF LONG-TERM THERAPY WITH A BIOSIMILAR OF ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA [0.03%]
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA患者长期使用ECULIZUMAB仿制药治疗的结果
Alexander D Kulagin,Vadim V Ptushkin,Elena A Lukina et al.
Alexander D Kulagin et al.
Introduction: The study aimed to assess the safety, immunogenicity, and efficacy of long-term therapy with biosimilar of eculizumab (Elizaria®) in PNH patients. ...
Thiamine-Responsive Megaloblastic Anemia Syndrome Mimicking Myelodysplastic Neoplasm [0.03%]
模仿骨髓增生性肿瘤的维生素B1依赖型巨幼红细胞性贫血综合征病例报告
Christina Klötzer,Franziska Schnabel,Anne-Sophie Kubasch et al.
Christina Klötzer et al.
Introduction: Thiamine-responsive megaloblastic anemia syndrome (TRMA) is a rare autosomal recessive disease with a homozygous or compound-heterozygous mutation in the SLC19A2 gene characterized by megaloblastic anemia, d...
Case Reports
Acta haematologica. 2024 Oct 28:1-5. DOI:10.1159/000542286 2024
Shorter Duration of Blinatumomab Administration to 14 Days Has Same Efficacy and Safety Profile in Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: A Retrospective Single-Center Study [0.03%]
为期14天的倍林妥莫双抗疗程在治疗复发/难治性B细胞前体急性淋巴细胞白血病中疗效和安全性相当：一项单中心回顾性研究
Jinyu Kong,Wenjing Miao,Jialing Lu et al.
Jinyu Kong et al.
Introduction: Treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (r/r BCP-ALL) remains a significant clinical challenge. Many new strategies are changing the treatment landscape o...
Efficacy of Haploidentical Allogeneic Hematopoietic Cell Transplantation following Two Courses of Venetoclax and Azacytidine Therapy in Patients over 55 Years Old with Acute Myelogenous Leukemia [0.03%]
序贯使用维奈克拉联合地西他滨和同种异体 haplo-HSCT 治疗大于 55 岁急性髓系白血病患者的疗效研究
Junjie Cao,Xianxu Zhuang,Danjie Luo et al.
Junjie Cao et al.
Introduction: The combination of venetoclax (VEN) and azacytidine (AZA) has demonstrated potential in achieving rapid and effective remissions in elderly patients with acute myeloid leukemia (AML). Allogeneic hematopoieti...